Form 4: Director Epperly Boosts Roivant Sciences Stake

Roivant Sciences Ltd. Director Melissa Epperly increased her direct beneficial ownership through a share award, partially offset by a tax-related disposition.

Summary

• Melissa B. Epperly, a Director of Roivant Sciences Ltd. (ROIV), reported changes in her beneficial ownership.
• On January 20, 2026, Ms. Epperly acquired 815 common shares as an award under the Issuer's Non-Employee Director Compensation Plan, which were fully vested on the grant date.
• Also on January 20, 2026, Ms. Epperly disposed of 54 common shares at a price of $22.98 per share.
• This disposition represents a 'net settlement' by the Issuer to satisfy applicable tax withholding obligations related to the vesting and settlement of the common shares.
• Following these transactions, Ms. Epperly's direct beneficial ownership stands at 57,665 common shares.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase or sale of equity securities.

Sentiment

Score: 7

Explanation: Director Melissa Epperly increased her direct beneficial ownership in Roivant Sciences Ltd. through a fully vested share award, partially offset by a tax-related disposition. This reflects standard non-employee director compensation and a net increase in insider holdings, which is generally viewed positively.

Positives

• Director Melissa Epperly received an award of 815 fully vested common shares, increasing her direct beneficial ownership in the company.
• The acquisition of shares aligns the director's interests more closely with those of shareholders.

Negatives

• A disposition of 54 shares occurred to cover tax withholding obligations, which is a standard practice but reduces the total shares held.

Risks

• No specific risks are identified beyond the general market risks associated with holding equity. The transaction date of January 20, 2026, which is in the future relative to the filing date of January 22, 2026, is noted as being pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.

Future Outlook

NA

Industry Context

This filing reflects a routine insider transaction related to director compensation, which is a common practice across publicly traded companies in all industries, including the biotechnology and pharmaceutical sectors where Roivant Sciences operates. It does not provide specific insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

• The award of common shares to a non-employee director as part of a compensation plan is a standard practice in corporate governance across various industries, including biotech.
• The 'net settlement' of shares to cover tax withholding obligations upon vesting is also a common and accepted method for managing equity compensation for directors and executives, consistent with practices observed in comparable companies.

Stakeholder Impact

• Shareholders may view the director's increased ownership as a positive signal of alignment with company interests and confidence in future performance.
• The transaction is part of the established non-employee director compensation plan, which is a standard aspect of corporate governance and stakeholder relations.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing, as it reports past and pre-planned transactions.

Key Dates

Recommendation

The filing details a routine insider transaction related to director compensation, involving a share award and a tax-related disposition. While it shows a slight net increase in beneficial ownership, it does not present new information significant enough to alter an investment thesis or warrant a strong buy or sell recommendation. The transaction is pre-planned and expected.

Keywords

Roivant Sciences, ROIV, Form 4, Insider Transaction, Director Compensation, Share Award, Beneficial Ownership, Equity Securities, Rule 10b5-1